Cargando…

Site-specific performance of (68)Ga-DOTATATE PET/CT in detecting tumors with ectopic adrenocorticotropic hormone secretion

OBJECTIVE: The aim of this study was to assess the detection ability of (68)Ga-DOTATATE in pulmonary versus extrapulmonary tumors with ectopic adrenocorticotropic hormone secretion (EAS). METHODS: Images of (68)Ga-DOTATATE PET/CT from 74 patients with suspected EAS were retrospectively reviewed. EAS...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Junhu, Luan, Zhonghua, Li, Ting, Guan, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348477/
https://www.ncbi.nlm.nih.gov/pubmed/37456258
http://dx.doi.org/10.3389/fonc.2023.1204963
_version_ 1785073673207545856
author Wang, Junhu
Luan, Zhonghua
Li, Ting
Guan, Xiaodong
author_facet Wang, Junhu
Luan, Zhonghua
Li, Ting
Guan, Xiaodong
author_sort Wang, Junhu
collection PubMed
description OBJECTIVE: The aim of this study was to assess the detection ability of (68)Ga-DOTATATE in pulmonary versus extrapulmonary tumors with ectopic adrenocorticotropic hormone secretion (EAS). METHODS: Images of (68)Ga-DOTATATE PET/CT from 74 patients with suspected EAS were retrospectively reviewed. EAS tumors were confirmed in 39 patients through surgical resection or biopsy. Image findings were compared with the histopathological results. RESULTS: EAS tumors were pathologically confirmed via surgery or biopsy in 39 patients. Among those 39 patients, 25 were with pulmonary neuroendocrine tumors (NETs), and the remaining 14 were with extrapulmonary NETs. (68)Ga-DOTATATE PET/CT correctly identified the tumor in 26 patients, rendering an overall detection rate of 66.7%. On a site-based analysis, (68)Ga-DOTATATE PET/CT correctly identified the EAS tumor in 13 of 25 patients with pulmonary NETs, yielding a detection rate of 52%; for the 14 patients with extrapulmonary NETs, (68)Ga-DOTATATE PET/CT correctly identified the EAS tumor in 13, yielding a detection rate of 92.9%. The detection rate of (68)Ga-DOTATATE was significantly higher in extrapulmonary NETs than in pulmonary NETs (92.9%% vs. 52%, P = 0.013). For the 13 patients with positive pulmonary NETs, the tumor SUVmax ranged from 1.1 to 7.4 with an average SUVmax of 3.1 ± 2.1. For the 13 patients with positive extrapulmonary NETs, the tumor SUVmax ranged from 2.7 to 21.8 with an average SUVmax of 9.9 ± 6.3. The tumor SUVmax was significantly higher in extrapulmonary tumors than pulmonary tumors (P = 0.015). The tumor size was smaller in pulmonary tumors than in extrapulmonary tumors, while the difference was not significant (P = 0.516). CONCLUSION: (68)Ga-DOTATATE showed site-specific difference in detecting tumors with EAS secretion. Specifically, (68)Ga-DOTATATE performed better in the extrapulmonary EAS tumors than in pulmonary ones with both higher detection rate and uptake. Combination of anatomic imaging techniques are necessary for the correct diagnosis of pulmonary EAS tumors.
format Online
Article
Text
id pubmed-10348477
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103484772023-07-15 Site-specific performance of (68)Ga-DOTATATE PET/CT in detecting tumors with ectopic adrenocorticotropic hormone secretion Wang, Junhu Luan, Zhonghua Li, Ting Guan, Xiaodong Front Oncol Oncology OBJECTIVE: The aim of this study was to assess the detection ability of (68)Ga-DOTATATE in pulmonary versus extrapulmonary tumors with ectopic adrenocorticotropic hormone secretion (EAS). METHODS: Images of (68)Ga-DOTATATE PET/CT from 74 patients with suspected EAS were retrospectively reviewed. EAS tumors were confirmed in 39 patients through surgical resection or biopsy. Image findings were compared with the histopathological results. RESULTS: EAS tumors were pathologically confirmed via surgery or biopsy in 39 patients. Among those 39 patients, 25 were with pulmonary neuroendocrine tumors (NETs), and the remaining 14 were with extrapulmonary NETs. (68)Ga-DOTATATE PET/CT correctly identified the tumor in 26 patients, rendering an overall detection rate of 66.7%. On a site-based analysis, (68)Ga-DOTATATE PET/CT correctly identified the EAS tumor in 13 of 25 patients with pulmonary NETs, yielding a detection rate of 52%; for the 14 patients with extrapulmonary NETs, (68)Ga-DOTATATE PET/CT correctly identified the EAS tumor in 13, yielding a detection rate of 92.9%. The detection rate of (68)Ga-DOTATATE was significantly higher in extrapulmonary NETs than in pulmonary NETs (92.9%% vs. 52%, P = 0.013). For the 13 patients with positive pulmonary NETs, the tumor SUVmax ranged from 1.1 to 7.4 with an average SUVmax of 3.1 ± 2.1. For the 13 patients with positive extrapulmonary NETs, the tumor SUVmax ranged from 2.7 to 21.8 with an average SUVmax of 9.9 ± 6.3. The tumor SUVmax was significantly higher in extrapulmonary tumors than pulmonary tumors (P = 0.015). The tumor size was smaller in pulmonary tumors than in extrapulmonary tumors, while the difference was not significant (P = 0.516). CONCLUSION: (68)Ga-DOTATATE showed site-specific difference in detecting tumors with EAS secretion. Specifically, (68)Ga-DOTATATE performed better in the extrapulmonary EAS tumors than in pulmonary ones with both higher detection rate and uptake. Combination of anatomic imaging techniques are necessary for the correct diagnosis of pulmonary EAS tumors. Frontiers Media S.A. 2023-06-30 /pmc/articles/PMC10348477/ /pubmed/37456258 http://dx.doi.org/10.3389/fonc.2023.1204963 Text en Copyright © 2023 Wang, Luan, Li and Guan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Junhu
Luan, Zhonghua
Li, Ting
Guan, Xiaodong
Site-specific performance of (68)Ga-DOTATATE PET/CT in detecting tumors with ectopic adrenocorticotropic hormone secretion
title Site-specific performance of (68)Ga-DOTATATE PET/CT in detecting tumors with ectopic adrenocorticotropic hormone secretion
title_full Site-specific performance of (68)Ga-DOTATATE PET/CT in detecting tumors with ectopic adrenocorticotropic hormone secretion
title_fullStr Site-specific performance of (68)Ga-DOTATATE PET/CT in detecting tumors with ectopic adrenocorticotropic hormone secretion
title_full_unstemmed Site-specific performance of (68)Ga-DOTATATE PET/CT in detecting tumors with ectopic adrenocorticotropic hormone secretion
title_short Site-specific performance of (68)Ga-DOTATATE PET/CT in detecting tumors with ectopic adrenocorticotropic hormone secretion
title_sort site-specific performance of (68)ga-dotatate pet/ct in detecting tumors with ectopic adrenocorticotropic hormone secretion
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348477/
https://www.ncbi.nlm.nih.gov/pubmed/37456258
http://dx.doi.org/10.3389/fonc.2023.1204963
work_keys_str_mv AT wangjunhu sitespecificperformanceof68gadotatatepetctindetectingtumorswithectopicadrenocorticotropichormonesecretion
AT luanzhonghua sitespecificperformanceof68gadotatatepetctindetectingtumorswithectopicadrenocorticotropichormonesecretion
AT liting sitespecificperformanceof68gadotatatepetctindetectingtumorswithectopicadrenocorticotropichormonesecretion
AT guanxiaodong sitespecificperformanceof68gadotatatepetctindetectingtumorswithectopicadrenocorticotropichormonesecretion